Royalty Pharma
110 East 59th Street
33rd Floor
New York
New York
10022
United States
Tel: (212)-883-0200
Fax: (212) 883-2260
Website: http://www.royaltypharma.com/
Email: info@royaltypharma.com
77 articles about Royalty Pharma
-
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
11/13/2023
Teva Pharmaceuticals International GmbH and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs.
-
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
10/19/2023
PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream.
-
The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.
-
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
9/5/2023
Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.
-
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
8/24/2023
Royalty Pharma plc and Ferring Pharmaceuticals announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.
-
The world's largest buyer of biopharma royalties is paying $300 million up front and $200 million in milestone payments for Ferring Pharmaceuticals’ FDA-approved bladder cancer drug Adstiladrin.
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
1/9/2023
Ionis Pharmaceuticals, Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® and Novartis' pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.
-
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
11/9/2022
Arrowhead Pharmaceuticals Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
-
Under the terms of the deal, Theravance and Innoviva are surrendering 85% and 15% of their stakes in Trelegy in exchange for $1.1 billion and $282 million from Royalty, respectively.
-
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
7/13/2022
Innoviva, Inc. announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC, which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc for an upfront cash payment of approximately $282 million and a potential $50 million contingent sales-based milestone payment.
-
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
7/13/2022
Theravance Biopharma, Inc. announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA to Royalty Pharma for over $1.5 billion in potential total value.
-
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
1/7/2022
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
11/22/2021
BioCryst Pharmaceuticals, Inc., Royalty Pharma plc and OMERS Capital Markets, announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
-
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
6/2/2021
MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
-
MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma
6/2/2021
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal. -
MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes
4/21/2021
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, to expand MSCI’s thematic index suite with the launch of new indexes
-
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
4/8/2021
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.